Peptide conjugation—covalently attaching peptides to proteins, polymers, or small molecules—expands the therapeutic utility of peptides by enhancing their properties or enabling new functions. The Peptide-Drug Conjugates CDMO Service Market was valued at USD 345.67 million in 2025 and is projected to reach USD 480.21 million by 2032[reference:107], reflecting the growing importance of this approach.
Peptide-protein conjugates are used to enhance immunogenicity for antibody production, where peptides are conjugated to carrier proteins like KLH or BSA. These conjugates are essential for generating antibodies against small peptides that are not immunogenic on their own. Peptide-protein conjugates are also used in vaccine development, where peptides are conjugated to immunogenic carriers to enhance immune responses.
Peptide-polymer conjugates, including PEGylated peptides, are used to enhance pharmacokinetic properties. The polymer chain increases molecular size, reducing renal clearance and extending half-life. Polymers can also improve solubility and reduce immunogenicity. Beyond PEG, other polymers including poly(ethylene glycol) and polysaccharides are used for peptide conjugation.
Peptide-small molecule conjugates, including peptide-drug conjugates (PDCs), are used for targeted drug delivery. The peptide targets the conjugate to specific cells or tissues, while the small molecule provides the therapeutic effect. PDCs offer advantages over antibody-drug conjugates, including smaller size, faster tumor penetration, and lower immunogenicity.
At PeptideHub, we provide custom peptide conjugation services using heterobifunctional linkers for controlled conjugation chemistries. Our experienced team can design and execute conjugation strategies for diverse applications, from antibody production to targeted drug delivery. We provide high-quality conjugates with full analytical documentation, supporting your research and development programs.